Luye Pharma products gain key reimbursement status in China

Luye Pharma Group Ltd. has announced the inclusion of five of its new products in either China's 2025 National Reimbursement Drug List for Basic Medical Insurance, Maternity Insurance and Work-Related Injury Insurance, or the 2025 Commercial Insurance Innovative Drug List. This development is expected to enhance affordability and market penetration for these treatments.

Among the newly covered products, Mimeixin (oxycodone hydrochloride and naloxone hydrochloride sustained-release tablets) and Ruibailai (paliperidone palmitate injection (II)) are included in the National Reimbursement Drug List for the first time. Zepzelca (lurbinectedin for injection) has been added to the Commercial Insurance Innovative Drug List, marking its place among China's inaugural entries to this list.

Furthermore, Baituowei (goserelin microspheres for injection) and Rykindo (risperidone microspheres for injection (II)) have successfully renewed their inclusion in the National Reimbursement Drug List. These inclusions are expected to alleviate patient burdens and support the long-term growth and market coverage of Luye Pharma's innovative drugs.